Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 340

Sort by

Sort Order Select

Journal Articles

A rapid genotyping panel for detection of primary central nervous system lymphoma

Blood (2021) 138 (5): 382–386.

https://doi.org/10.1182/blood.2020010137

Published: 2021

Includes: Supplemental data

Journal Articles

Sorting biologic subtypes of primary CNS lymphoma

Mark Roschewski, James D. Phelan

Blood (2021) 137 (11): 1436–1437.

https://doi.org/10.1182/blood.2020009968

Published: 2021

Journal Articles

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

Blood (2021) 137 (11): 1468–1477.

https://doi.org/10.1182/blood.2020008520

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma

Thomas A. Ollila, Habibe Kurt, Jozal Waroich, John Vatkevich, Ashlee Sturtevant, Nimesh R. Patel, Patrycja M. Dubielecka, Diana O. Treaba, Adam J. Olszewski

Blood (2021) 137 (8): 1120–1124.

https://doi.org/10.1182/blood.2020007236

Published: 2021

Includes: Supplemental data

Journal Articles

A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance

Jonathan Webster, MD, Richard F. Ambinder, MD, Richard J. Jones, MD, Nina D. Wagner-Johnston, MD, Gabrielle T. Prince, MD, Audra Shedeck, CRNP, Amanda Blackford, MS, Leo Luznik, MD, Ivana Gojo, MD

Blood (2019) 134 (Supplement_1): 778.

https://doi.org/10.1182/blood-2019-128255

Published: 2019

Journal Articles

Potential Genetic and Immunologic Mechanisms of Therapeutic Resistance and Disease Progression in CNS Lymphoma Elucidated Via Whole Brain Autopsy Studies

David A. Solomon, MD, PhD, Huimin Geng, PhD, Raymond A. Sobel, MD, Lakshmi Subbaraj, B.S., Mazie Tsang, MD, James L. Rubenstein, MD PhD

Blood (2019) 134 (Supplement_1): 1494.

https://doi.org/10.1182/blood-2019-131302

Published: 2019

Journal Articles

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Motoo Nagane, MD PhD, Yoshitaka Narita, MD PhD, Kazuhiko Mishima, MD PhD, Yasuhito Terui, MD PhD, Yoshiki Arakawa, MD PhD, Hajime Yonezawa, MD PhD, Katsunori Asai, MD PhD, Noriko Fukuhara, MD PhD, Kazuhiko Sugiyama, MD PhD, Naoki Shinojima, MD PhD, Junsaku Kitagawa, Arata Aoi, Ryo Nishikawa, MD PhD

Blood (2019) 134 (Supplement_1): 1586.

https://doi.org/10.1182/blood-2019-123362

Published: 2019

Journal Articles

Clinical Application of Circulating Tumor DNA in Plasma of Patients with Primary Central Nervous System Lymphoma

Sang Eun Yoon, Won Seog Kim, MD PhD, Seok Jin Kim, MD PhD, Young Hyeh Ko, MD, Kim Yeon Jeong, PhD, Park Donghyun, PhD

Blood (2019) 134 (Supplement_1): 1491.

https://doi.org/10.1182/blood-2019-130075

Published: 2019

Journal Articles

Phase Ib of Copanlisib in Combination with Ibrutinib in Recurrent/Refractory Primary CNS Lymphoma (PCNSL)

Christian Grommes, MD, Igor Gavrilovic, MD, Alexandra M Miller, MD PhD, Jacqueline B Stone, MD, Thomas Kaley, MD, Juli T Madzsar, Alyssa Schumpp, Brittany T Butler, Lauren Schaff, MD, Ingo K Mellinghoff, MD

Blood (2019) 134 (Supplement_1): 1598.

https://doi.org/10.1182/blood-2019-126214

Published: 2019

Journal Articles

Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas

Adam J Olszewski, MD, Anna D Chorzalska, PhD, Diana O Treaba, MD, John L Reagan, MD, Pamela C Egan, MD, Habibe Kurt, MD, James Butera, MD, William Rafelson, MDMBA, Alexander C Mohler, MD MS, Thomas A Ollila, MD, Rabin Niroula, MBBS, Jordan Robison, CRA, Chelsea D Mullins, BS, Patrycja M Dubielecka, PhD

Blood (2019) 134 (Supplement_1): 2800.

https://doi.org/10.1182/blood-2019-125475

Published: 2019

Journal Articles

CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma

Peter Herhaus, MD, Jana Lipkova, Felicitas Lammer, MD, Julia Slotta-Huspenina, MD, Benedikt Wiestler, MD, Tibor Vag, MD, Stefan Habringer, MD, Igor Yakushev, MD, Constantin Lapa, MD, Tobias Pukrop, MD, Dirk Hellwig, MD, Andreas Buck, MD, Martina Deckert, MD, Hans-Jürgen Wester, PhD, Florian Bassermann, MD PhD, Wolfgang Weber, MD, Markus Schwaiger, MD, Björn Menze, PhD, Ulrich Keller, MD

Blood (2019) 134 (Supplement_1): 2900.

https://doi.org/10.1182/blood-2019-126024

Published: 2019

Journal Articles

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Mark Roschewski, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Matthias Holdhoff, MD PhD, Lode J. Swinnen, MB ChB, Michael Glantz, MD PhD, Craig A. Portell, MD, Jakub Svoboda, MD, Rafic Farah, MD, Michail S. Lionakis, MD ScD, Louis Staudt, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2875.

https://doi.org/10.1182/blood-2019-123552

Published: 2019

Journal Articles

Expanding the Indications for Ibrutinib: Complete Remission Obtained By Induction with Ibrutinib Followed By Consolidative Ahsct in Refractory Primary CNS Lymphoma

Cassidy Brothers, MD MSC

Blood (2019) 134 (Supplement_1): 5631.

https://doi.org/10.1182/blood-2019-125378

Published: 2019

Journal Articles

Exploring the Safety and Efficacy of Upfront Autologous Stem Cell Transplantation with LEED Preconditioning for Primary Central Nervous System Lymphoma

Hirofumi Yokota, MD, Kotaro Miyao, MD PhD, Fumiya Ohara, MD, Kenta Motegi, MD, Hiroya Wakabayashi, MD, Yuki Takeuchi, MD, Shihomi Kuwano, MD, Hitomi Sawa, MD, Yuichiro Inagaki, MD PhD, Masashi Sawa, MD PhD

Blood (2019) 134 (Supplement_1): 1611.

https://doi.org/10.1182/blood-2019-123703

Published: 2019

Journal Articles

Outcomes for Patients with Primary or Secondary Central System Lymphoma Treated with Ibrutinib: A Multicentre Retrospective Analysis

Katharine L Lewis, FRCPath, MRCP, MBBS, Kate Manos, MBBS, John Casey, FRACP,FRCPA,MBBS, Julie Crawford, MDMBBS,FRACP, Shir-Jing Ho, FRACP,FRCPA,MBBS, Samar Issa, FRACP, Andrew Grigg, Peter Wood, Maher K. Gandhi, PhD, Eliza A Hawkes, Chan Y. Cheah

Blood (2019) 134 (Supplement_1): 1620.

https://doi.org/10.1182/blood-2019-125730

Published: 2019

Journal Articles

Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study

Alex G Sieg, MD MS, Christopher Strouse, MD, Sarah L Mott, Joshua Reeder, Sergei Syrbu, MD PhD, Guohua An, MD PhD, Grerk Sutamtewagul, MD, Brian K. Link, MD, Umar Farooq, MD

Blood (2019) 134 (Supplement_1): 1626.

https://doi.org/10.1182/blood-2019-127349

Published: 2019

Journal Articles

A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial

Blood (2019) 134 (Supplement_1): 2879.

https://doi.org/10.1182/blood-2019-122830

Published: 2019

Journal Articles

CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria

Blood (2019) 134 (Supplement_1): 2887.

https://doi.org/10.1182/blood-2019-129532

Published: 2019

Journal Articles

The B-Cell Receptor Antigen ARS2 Can be Integrated into a BAR-Body Format to Treat Diffuse Large B-Cell Lymphomas in Xenograft Mouse Models

Moritz Bewarder, MD, Christina Körbel, PhD, Matthias W. Laschke, PhD, Michael D. Menger, MD, Maximilian Kiefer, Dominic Kaddu-Mulindwa, MD, Helene Will, Lisa Goerens, Natalie Fadle, Evi Regitz, Stephan Stilgenbauer, Frank Neumann, PhD, Klaus Dieter Preuss, PhD, Michael Pfreundschuh, MD, Lorenz Thurner, MD

Blood (2019) 134 (Supplement_1): 2860.

https://doi.org/10.1182/blood-2019-131434

Published: 2019

Journal Articles

Central Nervous System Involvement in Peripheral T-Cell Lymphoma

Sangeetha Gandhi, MBBS, N. Nora Bennani, MD, Sonia Fortin, Thomas M. Habermann, MD, Patrick Johnston, MD, James R. Cerhan, MD PhD, Kay M. Ristow, BS, Carrie A. Thompson, MD, Grzegorz Nowakowski, MD, Yi Lin, MD PhD, Jose C Villasboas, MD, Luis Porrata, MD, Thomas E. Witzig, MD, Ivana Micallef, MD, David J Inwards, MD, Stephen M Ansell, MD PhD, Jonas Paludo, MD

Blood (2019) 134 (Supplement_1): 5293.

https://doi.org/10.1182/blood-2019-131965

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A rapid genotyping panel for detection of primary central nervous system lymphoma

Sorting biologic subtypes of primary CNS lymphoma

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma

A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance

Potential Genetic and Immunologic Mechanisms of Therapeutic Resistance and Disease Progression in CNS Lymphoma Elucidated Via Whole Brain Autopsy Studies

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Clinical Application of Circulating Tumor DNA in Plasma of Patients with Primary Central Nervous System Lymphoma

Phase Ib of Copanlisib in Combination with Ibrutinib in Recurrent/Refractory Primary CNS Lymphoma (PCNSL)

Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas

CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Expanding the Indications for Ibrutinib: Complete Remission Obtained By Induction with Ibrutinib Followed By Consolidative Ahsct in Refractory Primary CNS Lymphoma

Exploring the Safety and Efficacy of Upfront Autologous Stem Cell Transplantation with LEED Preconditioning for Primary Central Nervous System Lymphoma

Outcomes for Patients with Primary or Secondary Central System Lymphoma Treated with Ibrutinib: A Multicentre Retrospective Analysis

Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study

A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial

CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria

The B-Cell Receptor Antigen ARS2 Can be Integrated into a BAR-Body Format to Treat Diffuse Large B-Cell Lymphomas in Xenograft Mouse Models

Central Nervous System Involvement in Peripheral T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only